ImmunityBio, BeiGene Strike Deal to Conduct Phase III Trial for Tislelizumab, Anktiva in Advanced or Metastatic Non-Small Cell Lung Cancer

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung cancer who are PD-1 checkpoint inhibitor resistant.